HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful administration of quinupristin/dalfopristin in the outpatient setting.

Abstract
Intravenous administration of quinupristin/dalfopristin outside the hospital setting has not been reported previously. We describe 37 outpatients receiving quinupristin/dalfopristin iv for infections including osteomyelitis, bacteraemia, abscesses and cellulitis. The most frequent aetiological pathogens found were Enterococcus faecium, Staphylococcus aureus and coagulase-negative staphylococci. Patients received an average of 9 days therapy as inpatients and 22 days as outpatients. Quinupristin/dalfopristin was administered using various access devices, most commonly peripherally inserted central catheters and tunnelled central catheters. The bacteriological and clinical success rates were both 89.2%. Five patients were readmitted to hospital; one patient developed catheter-related bacteraemia. The most frequently reported non-venous adverse events were nausea (18.9% of patients), myalgia (18.9%) and arthralgia (13.5%). Sixteen patients experienced venous access-related events, most commonly infusion pain, oedema and phlebitis. In this group of patients, for those who had difficult-to-treat infections, intravenous quinupristin/dalfopristin therapy was generally effective and safe outside the hospital setting.
AuthorsS J Rehm, D R Graham, L Srinath, P Prokocimer, M P Richard, G H Talbot
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 47 Issue 5 Pg. 639-45 (May 2001) ISSN: 0305-7453 [Print] England
PMID11328776 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Virginiamycin
  • quinupristin-dalfopristin
Topics
  • Abscess (drug therapy)
  • Adult
  • Aged
  • Aged, 80 and over
  • Ambulatory Care
  • Bacteremia (drug therapy)
  • Drug Therapy, Combination (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Osteomyelitis (drug therapy)
  • Treatment Outcome
  • Virginiamycin (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: